Cidara Therapeutics report positive topline results released from STRIVE trial of lead antifungal

Cidara Therapeutics, Inc. (CA, USA) recently reported positive topline results from the international, multicenter, double-blind Phase II STRIVE clinical trial of its lead antifungal candidate rezafungin acetate.

Rezafungin is a novel antifungal echinocandin that has been developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections such as Candida.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment